ストックスクリーナーアプリを入手
121.51
0.71%
0.84
前日終値:
$120.67
開ける：
$120.34
24時間の取引高:
1.29M
Relative Volume:
0.19
時価総額：
$150.68B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
18.82
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
-0.06%
1か月 パフォーマンス:
+1.81%
6か月 パフォーマンス:
+7.32%
1年 パフォーマンス:
+36.33%
1日の値動き範囲:
$119.33
$121.90
1週間の範囲:
$116.88
$125.11
52週間の値動き範囲:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.45 | 149.71B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,103.72 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.06 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.11 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
112.39 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
142.76 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences, Inc. $GILD Position Lessened by Capital Investment Advisors LLC - MarketBeat
Will Gilead Sciences Inc. stock attract ESG investorsJuly 2025 Technicals & Real-Time Buy Signal Notifications - ulpravda.ru
Gilead Names Wettan Executive Vice President - BioXconomy
Gilead (GILD) Recalls Veklury Due to Contaminant Concerns - GuruFocus
What is the fair value of Gilead Sciences Inc. stock now2025 Top Gainers & Risk Controlled Stock Alerts - ulpravda.ru
Gilead presents positive data on liver fibrosis treatments - The Pharma Letter
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
Gilead Sciences, Inc. $GILD Holdings Decreased by Commonwealth Equity Services LLC - MarketBeat
Today's Analyst Action: Citigroup Raises Gilead Sciences (GILD) Price Target | GILD Stock News - GuruFocus
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
UBS Raises Gilead Sciences (GILD) Price Target to $145 and Upgra - GuruFocus
Gilead Sciences (NASDAQ:GILD) Given Buy Rating at UBS Group - MarketBeat
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum - Yahoo! Finance Canada
UBS raises Gilead Sciences stock price target to $145 on HIV drug outlook - Investing.com India
Gilead Sciences (NASDAQ:GILD) Nasdaq 100 Index Biopharma Scale - Kalkine Media
Key facts: Citi names Gilead Sciences a top biopharma pick; margin concerns rise - TradingView — Track All Markets
Assessing Gilead Sciences (GILD) Valuation After Mixed Near Term Returns And 9.4% Undervaluation Estimate - simplywall.st
Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact - BioSpace
OncoNano Medicine partners with Gilead to test drug delivery tech - Investing.com
OncoNano Medicine partners with Gilead to test drug delivery tech By Investing.com - Investing.com Canada
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate - Yahoo Finance
Robeco Institutional Asset Management B.V. Purchases 59,295 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
11,480 Shares in Gilead Sciences, Inc. $GILD Bought by TriaGen Wealth Management LLC - MarketBeat
Railway Pension Investments Ltd Purchases 42,200 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Truth About Gilead Sciences Inc (GILD): Hidden Giant or Boomer Stock Trap? - AD HOC NEWS
Gateway Investment Advisers LLC Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
SteelPeak Wealth LLC Sells 94,279 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Asset Management One Co. Ltd. - MarketBeat
Verity & Verity LLC Has $30.05 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Former Gilead exec who oversaw $20B in drug sales takes global role at autoimmune disease company - The Business Journals
AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals - Fierce Biotech
Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CapWealth Advisors LLC Has $27.04 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today - Sahm
Gilead Sciences Q3 EPS Forecast Raised by Zacks Research - MarketBeat
Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026 - Finviz
What's Driving the Market Sentiment Around Gilead Sciences Inc? - Benzinga
Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Ascent Group LLC Buys 11,926 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs - Finviz
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - sharewise.com
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead (GILD) reaches pricing agreement with US government to lower drug costs - MSN
Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
大文字化:
|
ボリューム (24 時間):